Back to search
FDAFDA · Food and drugs·Recall number D-0479-2017

Mimvey Lo (estradiol and norethindrone acetate tablets USP), 0.5 mg/0.1 mg, 28 tablets per blister card (NDC 0093-5454-18), packaged in 3 blister cards per carton (NDC 0093-5454-62), Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970; Manufactured For: Teva Pharmaceuticals USA, Sellersville, PA 18960.

Published February 22, 2017 · Recall initiated: February 2, 2017

Summary

FDA records drug Class II recall D-0479-2017, published February 22, 2017 and initiated February 2, 2017. Recalling firm: Teva Pharmaceuticals USA; Status: Terminated; Reported quantity: 17,473 cartons; Lot: Lot # 33809881A, Exp 05/17; 33811151A, Exp 08/17. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Teva Pharmaceuticals USA
Distributor
Nationwide in the United States
Lot
Lot # 33809881A, Exp 05/17; 33811151A, Exp 08/17
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Mimvey Lo (estradiol and norethindrone acetate tablets USP), 0.5 mg/0.1 mg, 28 tablets per blister card (NDC 0093-5454-18), packaged in 3 blister cards per carton (NDC 0093-5454-62), Rx only, Manufactured By: Barr Laboratories, Inc., Pomona, NY 10970; Manufactured For: Teva Pharmaceuticals USA, Sellersville, PA 18960. recalled?

Yes. FDA published recall D-0479-2017 on February 22, 2017. Reported hazard: Failed Impurities/Degradation Specifications: out of specification test results for the norethindrone impurity.

What should I do if I have this product?

Voluntary: Firm initiated · Letter